CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse
{{output}}
Relapse following anti-CD19 chimeric antigen receptor (CAR) T cell therapy remains a concern in the treatment of refractory B-cell malignancies. Although the CD19Δexon2 splice variant has been linked to treatment failure, reliable pre-treatment biomarkers for... ...
